Burning Rock Biotech (FRA:6BU0) Research & Development: €18.66 Mil (TTM As of Mar. 2026)


FRA:6BU0 Burning Rock Biotech Ltd FRA:6BU0
59 GF Score
Price €6.00
GF Value €5.43
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Research & Development?

Burning Rock Biotech FRA:6BU0 -17.81% 59 Research & Development is €18.66 Mil as of Mar. 2026. GuruFocus rates FRA:6BU0 with a GF Score™ of 59/100 and a GF Value™ of €5.43 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Burning Rock Biotech's Research & Development for the three months ended in Mar. 2026 was €3.46 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €18.66 Mil.

Burning Rock Biotech  (FRA:6BU0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Burning Rock Biotech Research & Development Related Terms

Burning Rock Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Burning Rock Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burning Rock Biotech Research & Development Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 51.11 57.12 44.57 30.47 20.19

Burning Rock Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.15 6.01 4.96 4.23 3.46
FRA:6BU0
59GF Score
Burning Rock Biotech Ltd FRA:6BU0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Burning Rock Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €18.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €18.66 Mil mean?
Burning Rock Biotech (FRA:6BU0) has a Research & Development of €18.66 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Research & Development too high?
Burning Rock Biotech's current Research & Development is €18.66 Mil. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Research & Development compare to FONR and XGN?
Burning Rock Biotech's Research & Development of €18.66 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Research & Development is €18.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.43, compared to a current price of €6.00 — trading 10.5% above its estimated fair value. The current Research & Development is €18.66 Mil. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Research & Development is €18.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of €6.00 is trading 10.5% above its estimated GF Value™ of €5.43. GuruFocus considers Burning Rock Biotech to be Modestly Undervalued.

Key valuation signals for FRA:6BU0:

  • Research & Development: €18.66 Mil
  • GF Value™: €5.43 vs. price of €6.00 (10.5% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges BNR:USA
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score

Get the complete analysis for FRA:6BU0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€5.43
GF Value